GasparyanAYStavropoulos-KalinoglouAMikhailidisDPTomsTEDouglasKMKitasGD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol. 2010;8(4):437–449.
6.
HenselerTChristophersE. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–986.
7.
McDonaldCJCalabresiP. Occlusive vascular disease in psoriatic patients. N Engl J Med. 1973;288(17):912.
8.
GelfandJMNeimannALShinDBWangXMargolisDJTroxelAB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741.
9.
GelfandJMDommaschEDShinDB, et al.The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411–2418.
10.
MehtaNNYuYPinnelasR, et al.Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.
11.
MehtaNNAzfarRSShinDBNeimannALTroxelABGelfandJM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006.
12.
ArmstrongEJHarskampCTArmstrongAW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062
13.
ArmstrongAWHarskampCTArmstrongEJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–442.
14.
YanoYBakrisGL. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013;7(3):244–252.
BacaksizAErdoganESonmezO, et al.Ambulatory blood pressure monitoring can unmask hypertension in patients with psoriasis vulgaris. Med Sci Monit. 2013;19:501–509.
17.
BacaksizAAkif VatankuluMSonmezO, et al.Non-dipping nocturnal blood pressure in psoriasis vulgaris. Wien Klin Wochenschr. 2012;124(23-24):822–829.
18.
TakeshitaJWangSShinDB, et al.Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol. 2015;151(2):161–169.
19.
ArmstrongAWLinSWChambersCJSockolovMEChinDL. Psoriasis and hypertension severity: results from a case-control study. PLoS One. 2011;6(3):e18227.
20.
ArmstrongAWHarskampCTArmstrongEJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91.
21.
ArmstrongAWHarskampCTArmstrongEJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.
22.
CasagrandeSSMenkeACowieCC. No association between psoriasis and diabetes in the U.S. population. Diabetes Res Clin Pract. 2014;104(3): e58–e60.
23.
JensenPRZachariaeCHansenPSkovL. Normal endothelial function in patients with mild-to-moderate psoriasis: a case-control study. Acta Derm Venereol. 2011;91(5):516–520.
24.
DuarteGVSilvaLP. Correlation between psoriasis’ severity and waist-to-height ratio. An Bras Dermatol. 2014;89(5):846–847.
25.
MaCHarskampCTArmstrongEJArmstrongAW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168(3):486–495.
26.
ArmstrongAWVoylesSVArmstrongEJFullerENRutledgeJC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci. 2011;63(1):1–9.
27.
ArmstrongAWHarskampCTDhillonJSArmstrongEJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304–314.
28.
EderLShanmugarajahSThavaneswaranA, et al.The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2012;71(2):219–224.
29.
PattisonEHarrisonBGriffithsCSilmanABruceI. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis. 2008;67(5):672–676.
30.
LiWHanJQureshiA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71(6):804–808.
31.
ManolisADoumasM. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26(11):2074–2084.
Molina-LeyvaAJimenez-MoleonJJNaranjo-SintesRRuiz-CarrascosaJC. Sexual dysfunction in psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(4):649–655.
34.
EgebergAHansenPRGislasonGHSkovLThyssenJP. Erectile dysfunction in male adults with atopic dermatitis and psoriasis. J Sex Med. 2017;14(3):380–386.
35.
BardazziFOdoriciGFerraraFMagnanoMBalestriRPatriziA. Sex and the PASI: patients affected by a mild form of psoriasis are more predisposed to have a more severe form of erectile dysfunction. J Eur Acad Dermatol Venereol. 2016;30(8):1342–1348.
36.
JiSZangZMaH, et al.Erectile dysfunction in patients with plaque psoriasis: the relation of depression and cardiovascular factors. Int J Impot Res. 2016;28(3):96–100.
37.
Molina-LeyvaAMolina-LeyvaIAlmodovar-RealARuiz-CarrascosaJCNaranjo-SintesRJimenez-MoleonJJ. Prevalence and associated factors of erectile dysfunction in patients with moderate to severe psoriasis and healthy population: a comparative study considering physical and psychological factors. Arch Sex Behav. 2016;45(8):2047–2055.
GhazizadehRShimizuHTosaMGhazizadehM. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7(5):284–289.
40.
ArmstrongAWVoylesSVArmstrongEJFullerENRutledgeJC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011;20(7):544–549.
41.
SimoniYDianaJGhazarianLBeaudoinLLehuenA. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?Clin Exp Immunol. 2013;171(1):8–19.
42.
ShahwanKTKimballAB. Psoriasis and cardiovascular disease. Med Clin North Am. 2015;99(6):1227–1242.
43.
RyanCKirbyB. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41–55.
44.
BaltaIBaltaSDemirkolS, et al.Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
45.
BaltaSBaltaIMikhailidisDP, et al.Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Am J Clin Dermatol. 2014;15(2):137–142.
46.
TroitzschPPaulista MarkusMRDörrM, et al.Psoriasis is associated with increased intima-media thickness—the Study of Health in Pomerania (SHIP). Atherosclerosis. 2012;225(2):486–490.
47.
YiuKHYeungCKZhaoCT, et al.Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med. 2013;273(3):273–282.
48.
GulluHCaliskanMDursunRCiftciOGuvenAMuderrisogluH. Impaired coronary microvascular function and its association with disease duration and inflammation in patients with psoriasis. Echocardiography. 2013;30(8):912–918.
49.
AtzeniFSarzi-PuttiniPSitiaS, et al.Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol. 2011;38(8):1661–1664.
50.
KatsikiNKoumarasCAthyrosVGKaragiannisA. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology. 2012;63(1):9–11.
51.
KoumarasCTzimouMStavrinouE, et al.Role of antihypertensive drugs in arterial ‘de-stiffening’ and central pulsatile hemodynamics. Am J Cardiovasc Drugs. 2012;12(3);143–156.
52.
VlachopoulosCXaplanterisPAboyansV, et al.The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507–532.
53.
YiuKHYeungCKChanHT, et al.Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol. 2011;164(3):514–520.
54.
AltekinERKoçSKarakaşMS, et al.Determination of subclinical atherosclerosis in plaque type psoriasis patients without traditional risk factors for atherosclerosis. Turk Kardiyol Dern Ars. 2012;40(7):574–580.
55.
BaltaIBaltaSDemirkolS, et al.Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology. 2014;65(1):74–78.
56.
BrezinskiEAFollansbeeMRArmstrongEJArmstrongAW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20(4):513–528.
57.
DattiloGImbalzanoECasaleM, et al.Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices. Angiology. 2018;69(1):31–37.
